SCIENCE@home

E‐selectin‐targeted copolymer reduces atherosclerotic lesions, adverse cardiac remodeling, and dysfunction

O. Tsoref,Dalia Tyomkin,U. Amit,N. Landa,Osnat Cohen-Rosenboim,David Kain,M. Golan,N. Naftali-Shani,A. David,J. Leor

Published 2018 in Journal of Controlled Release

ABSTRACT

ABSTRACT Endothelial activation with up‐regulation of E‐selectin adhesion molecules mediates leukocyte rolling along the vascular wall and controls inflammation in many diseases including atherosclerosis and heart failure. Therefore, we aimed to test the hypothesis that inhibition of E‐selectin‐mediated interactions by a new E‐selectin‐targeted copolymer could inhibit the progression of atherosclerosis. To target E‐selectin on activated endothelium, we developed a new N‐(2‐hydroxypropyl)methacrylamide (HPMA)‐based E‐selectin binding copolymer with or without dexamethasone (Dex) (designated P‐(Esbp)‐Dex and P‐Esbp, respectively). To determine the effect of P‐(Esbp)‐Dex and P‐Esbp on atherosclerosis, we allocated ApoE (−/−) mice on a high fat diet, to weekly intra‐peritoneal injections of either 1) P‐Esbp; 2) P‐(Esbp)‐Dex; 3) free Dex (1 mg/kg) or 4) saline, for four weeks. Aortic atherosclerosis and left ventricular (LV) remodeling and function were assessed by serial ultrasound studies and histology. Monocytes and macrophages were characterized by flow cytometry. After four weeks of treatment, P‐Esbp effectively targeted aortic atherosclerotic lesions. Both P‐Esbp and P‐(Esbp)‐Dex reduced wall thickening of the ascending aortas. However, only the drug‐free copolymer (P‐Esbp) significantly decreased the areas of necrotic core in the plaques and switched spleen macrophages toward an anti‐inflammatory (M2) phenotype. Furthermore, P‐Esbp attenuated adverse LV remodeling and dysfunction in ApoE (−/−) mice. In summary, P‐Esbp copolymer targets activated endothelial cells, regresses and stabilizes atherosclerotic plaques, and prevents adverse LV remodeling and dysfunction in ApoE (−/−) mice. Our results suggest a new, drug‐free macromolecular therapy to treat vascular inflammation. Graphical abstract Figure. No Caption available. HighlightsA “drug‐free” E‐selectin‐targeted copolymer binds to the surface of atherosclerotic plaques.Stabilizes and regresses atherosclerotic plaquesSwitches spleen macrophages toward an anti‐inflammatory phenotypeAttenuates adverse cardiac remodeling and dysfunction

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-50 of 50 references · Page 1 of 1

CITED BY

Showing 1-44 of 44 citing papers · Page 1 of 1